FI109125B - Förfarande för framställning av pamoatadditionssalt av risperidon - Google Patents

Förfarande för framställning av pamoatadditionssalt av risperidon Download PDF

Info

Publication number
FI109125B
FI109125B FI955166A FI955166A FI109125B FI 109125 B FI109125 B FI 109125B FI 955166 A FI955166 A FI 955166A FI 955166 A FI955166 A FI 955166A FI 109125 B FI109125 B FI 109125B
Authority
FI
Finland
Prior art keywords
risperidone
pamoate
compounds
addition salt
preparing
Prior art date
Application number
FI955166A
Other languages
English (en)
Finnish (fi)
Other versions
FI955166A (sv
FI955166A0 (sv
Inventor
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI955166A publication Critical patent/FI955166A/sv
Publication of FI955166A0 publication Critical patent/FI955166A0/sv
Application granted granted Critical
Publication of FI109125B publication Critical patent/FI109125B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (3)

1. Förfarande för framställning av ett terapeutiskt användbart pamoatsyraadditionssalt av risperidon med for-5 mein (I), O II r^r/YcH3 ^γ^ΟΗ
10 IA, (,) O S O 15 kännetecknat av att 3-[2-[4-(6-fluor-l,2-ben-s isoxazol-3-yl)-1-piperidinyl]etyl]-6,7,8,9-tetrahydro-2-metyl-4H-pyrido [1,2-a] pyrimin-4-on behandlas med pamoinsy-ra i ett reaktionsinert lösningsmedel.
2. Förfarande enligt patentkrav 1, k ä n n e -20 tecknat av att den framställda föreningen har for- meln q II ^ C—OH : ,\S ^V^-ch.-nc«2 o v_y \ j \=y F o .·. :30 • * · ,···.
3. Förfarande enligt patentkrav 1, kanne - t e c k n a t av att 3-[2-[4(6-fluor-l,2-bensisoxazol-3- * · \ ί y.l) l-piperidinyl] etyl] -6,7,8,9-tetrahydro-2-metyl-4H-pyri- do [1,2-a]pyrimidin-4-on behandlas med pamoinsyra i ett .,.,:35 reaktionsinert lösningsmedel. * · ·
FI955166A 1993-04-28 1995-10-27 Förfarande för framställning av pamoatadditionssalt av risperidon FI109125B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP93201216 1993-04-28
EP93201216 1993-04-28
EP9401296 1994-04-22
PCT/EP1994/001296 WO1994025460A1 (en) 1993-04-28 1994-04-22 Risperidone pamoate

Publications (3)

Publication Number Publication Date
FI955166A FI955166A (sv) 1995-10-27
FI955166A0 FI955166A0 (sv) 1995-10-27
FI109125B true FI109125B (sv) 2002-05-31

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955166A FI109125B (sv) 1993-04-28 1995-10-27 Förfarande för framställning av pamoatadditionssalt av risperidon

Country Status (32)

Country Link
US (2) US5612346A (sv)
EP (1) EP0697019B1 (sv)
JP (1) JP3478397B2 (sv)
KR (1) KR100307101B1 (sv)
CN (1) CN1041727C (sv)
AT (1) ATE163418T1 (sv)
AU (1) AU675136B2 (sv)
BG (1) BG62004B1 (sv)
CA (1) CA2160366C (sv)
CY (1) CY2107B1 (sv)
CZ (1) CZ286688B6 (sv)
DE (1) DE69408666T2 (sv)
DK (1) DK0697019T3 (sv)
ES (1) ES2113652T3 (sv)
FI (1) FI109125B (sv)
GR (1) GR3026028T3 (sv)
HK (1) HK1006059A1 (sv)
HU (1) HU218212B (sv)
IL (1) IL109448A (sv)
LV (1) LV12315B (sv)
NO (1) NO305083B1 (sv)
NZ (1) NZ266143A (sv)
PH (1) PH30476A (sv)
PL (1) PL182466B1 (sv)
RO (1) RO115955B1 (sv)
RU (1) RU2131428C1 (sv)
SG (1) SG47046A1 (sv)
SI (1) SI9420031B (sv)
SK (1) SK280589B6 (sv)
TW (1) TW376319B (sv)
WO (1) WO1994025460A1 (sv)
ZA (1) ZA942909B (sv)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA73715C2 (en) * 1997-09-30 2005-09-15 Lilly Co Eli Pharmaceutically acceptable formulation of olanzapine pamoate and its use for treatment
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
PT1468689E (pt) * 1998-09-30 2007-07-09 Lilly Co Eli Formulação de 2-metil-tieno-benzodiazepina.
AU1816900A (en) * 1998-11-12 2000-05-29 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534288A1 (en) * 2002-08-23 2005-06-01 Ranbaxy Laboratories, Ltd. Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US7932249B2 (en) * 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
BRPI0815382A2 (pt) * 2007-07-31 2015-02-10 Otsuka Pharma Co Ltd Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento
DK2234617T3 (da) * 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
EP4327872A3 (en) 2011-03-18 2024-07-10 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US9040695B2 (en) * 2011-04-26 2015-05-26 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
NZ630428A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
AU2013245011B2 (en) 2012-04-04 2017-11-23 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
CN102659577B (zh) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 一种亚甲基双羟基萘酸的制备方法
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技(厦门)有限公司 可乐定双羟萘酸盐及其制备方法
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
FI955166A (sv) 1995-10-27
HU218212B (hu) 2000-06-28
HK1006059A1 (en) 1999-02-05
BG62004B1 (bg) 1998-12-30
HU9501934D0 (en) 1995-09-28
IL109448A0 (en) 1994-07-31
HUT72970A (en) 1996-06-28
US5723467A (en) 1998-03-03
SI9420031A (en) 1996-08-31
JP3478397B2 (ja) 2003-12-15
PH30476A (en) 1997-05-28
LV12315A (lv) 1999-07-20
CN1121719A (zh) 1996-05-01
SK280589B6 (sk) 2000-04-10
KR100307101B1 (ko) 2001-11-30
ZA942909B (en) 1995-10-26
JPH08509482A (ja) 1996-10-08
DE69408666D1 (de) 1998-04-02
AU6721694A (en) 1994-11-21
RU2131428C1 (ru) 1999-06-10
AU675136B2 (en) 1997-01-23
PL311282A1 (en) 1996-02-05
NO954275D0 (no) 1995-10-26
WO1994025460A1 (en) 1994-11-10
BG100094A (bg) 1996-05-31
FI955166A0 (sv) 1995-10-27
DK0697019T3 (da) 1998-09-28
ES2113652T3 (es) 1998-05-01
IL109448A (en) 1997-03-18
CN1041727C (zh) 1999-01-20
SK131395A3 (en) 1996-06-05
LV12315B (en) 2000-03-20
US5612346A (en) 1997-03-18
CA2160366A1 (en) 1994-11-10
NZ266143A (en) 1996-07-26
CZ286688B6 (en) 2000-06-14
GR3026028T3 (en) 1998-04-30
CY2107B1 (en) 2002-04-26
DE69408666T2 (de) 1998-06-18
SI9420031B (sl) 2002-08-31
NO954275L (no) 1995-10-26
CZ270695A3 (en) 1996-01-17
PL182466B1 (pl) 2002-01-31
NO305083B1 (no) 1999-03-29
RO115955B1 (ro) 2000-08-30
SG47046A1 (en) 1998-03-20
TW376319B (en) 1999-12-11
EP0697019A1 (en) 1996-02-21
CA2160366C (en) 2006-06-06
EP0697019B1 (en) 1998-02-25
ATE163418T1 (de) 1998-03-15

Similar Documents

Publication Publication Date Title
FI109125B (sv) Förfarande för framställning av pamoatadditionssalt av risperidon
CA2626134C (en) Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP0960106B1 (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
JP2010095550A (ja) キノリン誘導体
WO1993016698A1 (en) SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES
EP0393696A2 (en) 7-(Substituted)amino)-8-(substituted)Carbonyl)-methylamino-1-oxaspiro (4,5)decanes as diuretics antiinflammatory, and cerebrovascular agents
TW593302B (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
US4663456A (en) 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders
US20060069096A1 (en) Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma
US3632653A (en) Ethano-anthracenes
KR20010086448A (ko) 벤즈옥사졸 유도체 및 유효 성분으로서 이를 포함하는 의약
US7439262B1 (en) Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma
IE42161B1 (en) Pyrano-quinoline carboxylic acids,processes for their preparation and their use as pharmaceutical agents
WO2014066840A1 (en) Aurora kinase inhibitors
HU204821B (en) Process for producing endo-n-braces open brackets open (8-methyl-8-azabicyclo/3,2,1/octan-3/yl)-amino brackets closed -carbonyl braces closed-2-(cyclopropylmethoxy)-benzamide, its salts and pharmaceutical compositions comprising such compounds as active ingredient
EP0373658A2 (en) Use of quinoline derivatives in treating cancer
US5489607A (en) Use of enadoline in the treatment of benign prostatic enlargement
WO1995003803A1 (en) SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES
ITMI941462A1 (it) Derivati eterociclo-condensati di morfinoidi
DD150204A5 (de) Verfahren zur herstellung von [2,3-e]-as-triazin-derivaten

Legal Events

Date Code Title Description
MA Patent expired